Evidence map›Paper›PMID 35092364›Full record

ArticleBiotechnology progress2022

Proceedings from the 3rd International Conference on Microbiome Engineering.

Sandra McClure, Fatima Enam, Jack Arnold, Mark Mimee

Abstract read
In one paragraph

Article in Biotechnology progress, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sandra McClureCommittee on Molecular Metabolism & Nutrition, the University of Chicago, Chicago, Illinois, USA.
Fatima EnamDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Jack ArnoldPritzker School of Molecular Engineering, The University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-4840-1327
Mark MimeePritzker School of Molecular Engineering, The University of Chicago, Chicago, Illinois, USA.ORCID 0000-0002-3083-2671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human microbiome has been inextricably linked to multiple facets of human physiology. From an engineering standpoint, the ability to precisely control the composition and activity of the microbiome holds great promise for furthering our understanding of disease etiology and for new avenues of therapeutic and diagnostic agents. While the field of microbiome research is still in its infancy, growing engineering efforts are emerging to enable new studies in the microbiome and to rapidly translate these findings to microbiome-based interventions. At the 3rd International Conference on Microbiome Engineering, leading experts in the field presented state-of-the-art work in microbiome engineering, discussing probiotics, prebiotics, engineered microbes, microbially derived biomolecules, and bacteriophage.

Indexed as

BacteriophagesMicrobiotaProbioticsBone and BonesHumansPrebioticsPrebioticsbacteriophagemetabolic engineeringmicrobiomeprobioticssynthetic biology

Identifiers

PMID35092364
PMCPMC9286688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.